New framework to identify genetic risk of disease could lead to targeted therapeutics

Genome-wide association studies (GWAS) on patient blood samples are useful for identifying the genetic basis of blood cell traits and their links to common diseases. While previous experiments have focused on characterizing clinical parameters such as cell count, few have evaluated the dynamic effects of factors—such as inflammation, microbiome or medications—on blood cell contributions to disease development and progression.